BACKGROUND: Peripheral administration of glucagon-like peptide-1 (GLP-1) for four hours, to normal weight and obese humans, decreases food intake and suppresses appetite. OBJECTIVE: The aim of this study was to assess the effect of an eight hour infusion of GLP-1 on appetite and energy intake at lunch and dinner in obese subjects. DESIGN: Randomised, blinded cross-over design with intravenous infusion of GLP-1 (0.75 pmol Á kg 71 Á min 71 ) or saline. SUBJECTS: Eight obese (body mass index, BMI, 45.5 AE 2.3 kgam 2 ) male subjects. MEASUREMENTS: Ad libitum energy intake at lunch (12.00 h) and dinner (16.00 h) after an energy ®xed breakfast (2.4 MJ) at 08.00 h. Appetite sensations using visual analogue scales, (VAS) immediately before and after meals and hourly in-between. Blood samples for the analysis of glucose, insulin, C-peptide, GLP-1 and peptide YY. Gastric emptying after breakfast and lunch using a paracetamol absorption technique. RESULTS: Hunger ratings were signi®cantly lower with GLP-1 infusion. The summed ad libitum energy intake at lunch and dinner was reduced by 1.7 AE 0.5 MJ (21 AE 6%) by GLP-1 infusion (P 0.01). Gastric emptying was delayed by GLP-1 infusion, and plasma glucose concentrations decreased (baseline: 6.6 AE 0.35 mmolaL; nadir: 5.3 AE 0.15 mmolaL). No nausea was recorded during GLP-1 infusion. CONCLUSIONS: Our results demonstrate that GLP-1 decreases feelings of hunger and reduces energy intake in obese humans. One possible mechanism for this ®nding might be an increased satiety primarily mediated by gastric vagal afferent signals.
Introduction
Glucagon-like peptide-1 amide (GLP-1) is a peptide of 30 amino acids produced in, and secreted from, L-cells of the intestinal mucosa into the circulation, after intake of a mixed meal. 1, 2 By exerting a receptor-mediated insulinotropic action on the pancreatic b-cell in the postprandial state, GLP-1 is considered an incretin. GLP-1 also inhibits gastric emptying and acid secretion and is, as such, a candidate mediator of the`ileal brake'. 1 GLP-1 has been shown to affect food intake. In the rat brain, GLP-1 immunoreactive cell bodies and nerve ®bres are found in areas of the brain that receive afferents from the gastrointestinal tract via the vagal nerves and control food intake. 3, 4, 5, 6 Intracerebroventricular (ICV) injection of GLP-1 in rodents, inhibits food intake. 7 ± 9 In addition, central administration of GLP-1 has been shown to inhibit the intake of water. 8 The ICV administration of exendin amide, a GLP-1 receptor antagonist, to satiated, but not fasted rats, increases food intake. 9 Indeed, administration of exendin (9-39)amide twice daily over 10 d, has been shown to increase food intake and results in a signi®cant weight gain in treated rats. 10 Studies in normal weight humans, have shown that peripheral administration of GLP-1 decreases food intake and suppresses appetite. 11, 12 Obese subjects may have an attenuated release of GLP-1 in response to meals. 13, 14 In a previous study, we demonstrated that intravenous infusion of GLP-1, for four hours, to six obese subjects, resulted in lower hunger ratings over four hours after the start of infusion. Concomitantly with the start of GLP-1 infusion, a meal was eaten on a universal eating monitor. No effect of GLP-1 was seen on food intake parameters. 15 The aim of the present study was therefore to extend these studies and to examine if GLP-1 administered intravenously for 8 h to obese humans, affects appetite and energy intake at an anticipated meal. In order to study one possible mechanism of GLP-1 action on food intake, the rate of gastric emptying was studied using a paracetamol absorption technique.
Experimental subjects
Eight male obese subjects (meanAE s.e.m., body mass index (BMI) 45.5 AE 2.3 kgam 2 and aged 35.0 AE 3.8 y)
were recruited from patients attending the outpatient Obesity Unit at the Huddinge University Hospital. Two patients were taking medication for hypertension, but the remaining subjects were not taking any medication. Informed consent was obtained from all subjects and the study was approved by the Ethics Committee of the Karolinska Hospital.
Material and methods

Study protocol
The subjects were instructed to fast from midnight before the study and refrain from alcohol consumption and exercise for 24 h prior to the study day. They reported to the Obesity Unit at 07.15 h in the morning and an indwelling catheter was placed in each antecubital vein. The study was performed in a randomised double-blind, cross-over fashion on two occasions, one week apart. Simultaneously with the onset of intake of a ®xed energy breakfast at 08.00 h, either GLP-1 (0.75 pmolakgamin)(Bachem AG, Bubendorf, Switzerland) dissolved in 0.9% saline containing 1% albumin (Albumin Kabi 200 mgaml), subjected to sterile ®ltration and stored at 7 20 C until use or saline was started in one of the intravenous catheters and continued for eight hours. For infusion, an Infusor SV (Baxter, Swinford, Eire) 5 mlah was used. Free access to drinking water was allowed throughout the day.
Meals and the universal eating monitor
Breakfast was served at 08.00 h and consisted of bread (55 g), butter (15 g), cheese (60 g) and orange juice (200 g). The energy content was 2.4 MJ (protein 22.6 g (16 energy (E)%), carbohydrate 49.6 g (36 E%), fat (30.9 g (48 E%)). At 12.00 h and 16.00 h an ad libitum test meal was served on a universal eating monitor (VIKTOR). The VIKTOR has been described in detail elsewhere. 16 In short, the VIKTOR-equipment consists of a hidden scale built into a table and connected to a computer. A homogenous meal in excess, is placed on a plate and the subjects are instructed to eat until satis®ed. The total food intake, meal duration, eating rate (initial and total) and rate of deceleration were measured by VIKTOR. The test meal at 12.00 h was an industrially produced pasta dish (Pasta Bolognese, Nestle Â, Bjuv, Sweden) with the addition of 6.5 g fata100 g pasta. This resulted in a meal of 0.7 MJa100 g (protein 5 g (13 E%), carbohydrate 15 g (38 E%) and fat 9 g (49 E%)). For dinner an industrially produced Swedish hash with a standard energy content of 0.7 MJa100 g (protein 5 g (13 E%), carbohydrate 14 g (37 E%) and fat 9 g (50 E%)), consisting of diced meat, onions and potatoes (Oxpytt, Nestle Â, Bjuv, Sweden) was served.
Assessment of appetite and nausea
The desire to eat, hunger, fullness, prospective consumption and feeling of nausea, were studied with visual analogue scales (VAS) 17 15 min before, 15 min after, and hourly in between, meals. After completion of lunch and dinner, the subjects were asked to assess the pleasantness of each meal using a VAS. 7 20 C for analysis in one series.
Glucose was analysed using an enzyme assay (mutarotase and glucose dehydrogenase) (BoeringerMannheim GmbH, Mannheim, Germany) using a Hitachi 917 automatic analyser.
Insulin was analysed using an enzyme immunoassay (DAKO Insulin Kit K6219, Copenhagen, Denmark). The assay cross-reacts to 0.3% with proinsulin but not with C-peptide. The detection limit of the assay was 3 mUaL and the intra-assay coef®cient of variation was 8%.
C-peptide concentrations in plasma were determined by a radioimmunoassay (RIA) (Euro-Diagnostica, Malmo È, Sweden). The assay cross-reacts to proinsulin by 41%, but not with insulin. The detection limit was 50 nmolaL and the intra-assay coef®cient of variation was 5%.
GLP-1-like immunoreactivity in plasma was studied using RIA speci®c for each terminus of the molecule. N-terminal immunoreactivity was measured using a newly described antiserum 18 raised in rabbits against synthetic proglucagon 78 ± 87 with a C-terminal cysteine coupled to keyhole limpet hemocyanin using the cystein thiol method. The selected antiserum (code 93242) was used in a ®nal dilution of 1:15000, and has a detection limit of 5 pmolaL. The antiserum has a cross-reactivity of approximately 10% with GLP-1 (1 ± 36)amide and 0.1% with GLP-1 (8 ± 36)amide and GLP-1 (9 ± 36)amide. High performance liquid chromatography (HPLC) supports the use of RIA with this speci®city to measure concentrations of intact GLP-1.
19 C-terminal immunoreactivity was measured using antiserum 89390, 20 which has an absolute requirement for the intact amidated C-terminus of GLP-1 (7 ± 36)amide, and cross-reacts 0.01% with truncated fragments, and 83% with GLP-1 (9 ± 36)amide. For all assays, the intra-assay coef®cient of variation was`6%. GLP-1 (7 ± 36)amide was used as standard, and 125 I-labelled GLP-1 (7 ± 36)amide as tracer. Before analysis GLP-1, appetite and energy intake E Na Èslund et al plasma was extracted with 70% ethanol (volavol, ®nal concentration) before assay, giving recoveries of 75%. Separation was achieved using plasmacoated charcoal.
PYY-like immunoreactivity was analysed using antiserum code no. 8412-2II (a gift from R. Ha Êkanson, Dept of Pharmacology, University of Lund, Lund, Sweden) raised in rabbits against synthetic porcine PYY 1 ± 36 (Peninsula Europe, Merseyside, UK) as previously described, 21 but without conjugation to carrier protein. 22 The antiserum cross-reacts 100% with human PYY. The detection limit of the assay was 1 pmolaL and the intra-assay coef®cient of variation was 5%.
Gastric emptying
The rate of gastric emptying, was assessed by utilising paracetamol absorption from the intestine after oral ingestion as a marker. 23 Plasma concentrations of paracetamol were assessed at the time points described above, after ingestion of paracetamol (1.5 g) dissolved in 200 ml of water with breakfast and lunch. Analysis of paracetamol was assessed bȳ uorescence-immunoassay (IMX, Abbott Laboratories, Chicago, IL). The intra-assay coef®cient of variation was 5%.
Statistics and calculations
All values are mean AE s.e.m. or median (range) as appropriate and P`0.05 was considered statistically signi®cant. Appetite and nausea ratings (VAS) were analysed by calculating inter-meal delta values (change in rating between the value after breakfast (08.15 h) and before lunch (11.45 h); and the value after lunch (12.15 h) and before dinner (15.45 h)). These delta values and the results of the VIKTOR, were analysed using Wilcoxon signed rank test for matched pairs. Plasma concentrations of glucose, insulin, C-peptide, N-terminal GLP-1, C-terminal GLP-1 and PYY were analyzed employing an ANOVA with repeated, paired measures with time and treatment as factors.
The gastric emptying pro®le was estimated after conversion of plasma paracetamol concentration values to cumulated values, re¯ecting total absorption of the drug. The inverted absorption values signi®es the absorption of the drug in relation to maximal absorption during saline infusion. Each individual gastric emptying curve was adapted to a third-degree polynomial. For repeated paracetamol administration, the remaining plasma concentrations from the ®rst administration, were subtracted according to the elimination rate of the drug, according to its terminal elimination phase. For statistical analysis the actual plasma paracetamol concentrations values were used and analysed employing an ANOVA with repeated, paired measures with time and treatment as factors.
Results
Food intake and eating rate
After the energy ®xed breakfast, GLP-1 infusion resulted in reduced food intake and slower overall eating rate at the ad libitum lunch and dinner ( Table  1 ). The summed reduction in energy intake at lunch and dinner during GLP-1 infusion, was 1.7 AE 0.5 MJ (21 AE 6% reduction) (P 0.01). There was no difference in eating parameters, such as initial eating rate or eating curve (accelerating vs decelerating) measured on the universal eating monitor during GLP-1 or saline infusion.
Appetite ratings, test meal palatability and nausea
In the control treatment, hunger ratings decreased after breakfast (08.00 h). Thereafter hunger ratings rose gradually until before lunch (11.45 h), and decreased again after lunch (12.00 h) to rise again until before dinner (15.45 h). A similar pattern was seen after GLP-1 infusion, but the ratings were lower. GLP-1 infusion resulted in a smaller increase in ratings of hunger (P`0.05) and prospective consumption (P`0.05) and a corresponding decrease in ratings of fullness (P`0.05) during the period between breakfast and lunch. The difference in ratings of desire to eat, was not quite signi®cant (P 0.07). The change in appetite ratings between lunch and dinner showed a similar pattern (hunger (P 0.01), desire to eat (P`0.05), prospective consumption (P 0.07) and fullness (P 0.09) (Figure 1) . Meal palatability at lunch was similar during saline (79.4 (55 ± 100)) and GLP-1 (77.9 (56 ± 89)) (P 0.57) infusion and at dinner during saline (69.0 (2 ± 91)) and GLP-1 (49 (2 ± 93)) (P 0.16) infusion. There were no differences in feelings of nausea during GLP-1 or saline infusion (Figure 2 ).
Gastric emptying
Gastric emptying was slower during GLP-1 infusion, as re¯ected by a reduced absorption rate of paracetamol (P`0.001). Both the rate of gastric emptying after breakfast and after lunch was slower during GLP-1 infusion, with approximately 50% reduced Table 1 Results of the universal eating monitor (VIKTOR) characteristics during infusion of saline (NaCl) and glucagonlike peptide-1 (GLP-1) in obese human subjects GLP-1, appetite and energy intake E Na Èslund et al absorption of paracetamol compared to controls ( Figure 3 ).
Glucose, insulin, C-peptide, GLP-1 and PYY
Plasma glucose concentrations were elevated after breakfast and lunch in the control setting, while GLP-1 infusion resulted in lower glucose concentrations ( Figure 4 , P`0.001). Plasma C-peptide concentrations were higher during saline infusion (P 0.01), whereas no difference in plasma concentrations of insulin were seen between GLP-1 and saline infusions ( Figure 4 ). PYY concentrations were lower during infusion with GLP-1 ( Figure 5 , P`0.001). Infusion of GLP-1 at 0.75 pmolakgamin resulted in a six-fold elevation of C-terminal plasma GLP-1 concentrations (approx. 20 vs 120 pmolaL), and a 2.5-fold elevation of the biologically active N-terminal GLP-1 (approx. 6 vs 16 pmolaL) (P`0.001, respectively) ( Figure 5 ).
Discussion
This study demonstrates that peripherally administered GLP-1 in slightly supraphysiological concentrations, 24 decreased hunger and reduced energy intake in Figure 1 Mean AE s.e.m. appetite ratings (hunger, fullness, desire to eat, and prospective consumption) during glucagon-like peptide-1 (GLP-1, ®lled circles) and saline (®lled squares) infusion in eight obese male subjects. An energy ®xed breakfast (2.4 MJ) was served at 08.00 h and an ad libitum lunch and dinner at 12.00 h and 16.00 h, respectively. Data were analysed using Wilcoxon signed rank test for matched pairs to determine the change in rating between breakfast and lunch, and lunch and dinner (between breakfast and lunch: hunger (P`0.05), fullness (P`0.05), desire to eat P 0.07 and prospective consumption (P`0.05); between lunch and dinner: hunger (P 0.01), fullness (P 0.09), desire to eat (P`0.05) and prospective consumption (P 0.07). Figure 2 Mean AE s.e.m. nausea ratings during glucagon-like peptide-1 (GLP-1, ®lled circles) and saline (®lled squares) infusion in eight obese male subjects. An energy ®xed breakfast (2.4 MJ) was served at 08.00 h and an ad libitum lunch and dinner at 12.00 h and 16.00 h, respectively. Data were analysed using Wilcoxon signed rank test for matched pairs to determine the change in rating between breakfast and lunch, and lunch and dinner. (No signi®cant difference between breakfast and lunch, and lunch and dinner, respectively).
GLP-1, appetite and energy intake E Na Èslund et al obese men. Concomitantly, gastric emptying was delayed by GLP-1. These results extend and con®rm those seen in our previous study, where GLP-1 was infused for four hours in obese subjects. 15 In that study, GLP-1 infusion was initiated at the start of a test meal and appetite ratings were monitored for four hours. No difference was seen in energy intake parameters, but postprandial hunger ratings were lower during GLP-1 compared to saline infusions. In the present study, the appetite rating pro®les were similar to those in our short-term study, 15 but in addition we found a signi®cant reduction in energy intake at lunch and dinner. Reduced appetite ratings and decreased energy intake have also been demonstrated in normal weight male subjects during GLP-1 infusion for four hours. 11 It has previously been shown that the eating rate increases as hunger increases 25 and the eating rate is low when the hunger drive is low. 26 The eating rate was slower both at lunch and dinner during GLP-1 infusion, compared to saline. Thus it is possible that GLP-1 reduces the eating-drive.
It has been suggested that the effect of GLP-1 on food intake in rodents may be due to a centrally evoked taste aversion. 27 We were, however, unable to detect any change in palatability (pleasantness of the meal) of the test meals in this study or our previous shorter study 15 or change in nausea ratings during GLP-1 compared to saline infusion our obese men. Similar results on palatability ratings were also demonstrated in the recent study on the effect of GLP-1 on food intake in normal weight men. 11 The test meal used in studies with the VIKTOR, is a standard Swedish lunch hash, which has a high fat content. 16 In order to have the same energy distribution at lunch and dinner, fat was added to the pasta dish. As the test meals used in this study are high in fat, it raises the question of whether the GLP-1 effect on food intake is dependent on a high fat diet. However, in the study of Flint et al, 11 the fat content was lower and in our short-term study, we could not detect any speci®c selection of food items in a food choice list during GLP-1 infusion compared to saline, 15 suggesting that the effect of GLP-1 is not limited to a high fat diet. In this study, access to water was unlimited and no Figure 4 Mean AE s.e.m. plasma glucose, insulin and C-peptide concentrations during glucagon-like peptide-1 (GLP-1, ®lled circles) and saline (®lled squares) infusion in eight obese male subjects. An energy ®xed breakfast (2.4 MJ) was served at 08.00 h and an ad libitum lunch and dinner at 12.00 h and 16.00 h, respectively. By ANOVA with repeated measures, time, treatment and treatment Â time interaction effect, all P`0.001 (glucose), P`0.001, P 0.47, P 0.01, respectively (C-peptide) and P`0.001, P 0.65, P 0.13, respectively (insulin).
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Several mechanisms by which GLP-1 inhibits energy intake and decreases feelings of hunger, can be envisioned. Previous studies show that GLP-1 inhibits gastric emptying in normal weight volunteers, 28, 29 as well as obese subjects, 15 and these results were con®rmed in this study. The decreased PYY concentrations in plasma, are also most likely to be a result of this retarded rate of gastric emptying seen during GLP-1 infusion. The slower gastric emptying, results in a prolonged period of gastric distension and a more sustained delivery of nutrients to the small intestine. In humans, satiety is induced if an emulsion of lipid is infused into the duodenum at the same time as the stomach is distended, 30 and hunger is suppressed if lipid is infused into the jejunum without gastric distension. 31 The gastrointestinal tract is equipped with mechano-and chemosensitive receptors, which relay information to the central nervous system via the vagus nerve. 32 It is possible that the decreased gastric emptying rate, seen after infusion of GLP-1, results in a prolonged stimulation of mechanoand chemosensitive receptors in the stomach and small intestine, which may lead to prolonged satiety and decreased appetite.
GLP-1 has been shown to cross the blood-brain barrier via the subfornical organ and area postrema of the circumventricular organs. 33 Activation of GLP-1 receptors in the areas of the brain which control feeding by means of ICV injection of GLP-1 in rodents results in inhibition of food intake.7,8,9 Thus, it is also possible that peripherally administered GLP-1 exerts its effect via a central mechanism. Both the GLP-1 receptor and GLP-1-like immunoreactivity are found in the hypothalamus. 34 There is, however, no evidence of an increased hypothalamic postprandial GLP-1 secretion. Contrary to the assumption of a central satiating effect of peripherally administered GLP-1 on food intake, there is no effect on food intake after intraperitoneal injection of GLP-1 in rats. 8, 9 This could be interpreted to indicate that GLP-1 receptors in the hypothalamus are not accessible for peripherally administered GLP-1. Yet, GLP-1 is metabolized very rapidly in rats, 35 which may explain the ineffectiveness of peripherally administered GLP-1 on food intake in rodents. The study of Gutzweiler et al 12 supports the concept of a central mechanism of GLP-1 in man. Here, GLP-1 was infused one hour prior to food intake in human subjects and energy intake was reduced in a dosedependent manner. In addition, feelings of hunger were reduced in the period before the test meal. This suggests that peripheral in¯uences, such as gastric signals of fullness and the activation of intestinal mechano-or chemoreceptors, are less likely to play a signi®cant role for the satiating effect of GLP-1. Taken together, these ®ndings indicate that GLP-1, perhaps like cholecystokinin, 36 may exert its effect on food intake and appetite via interaction with sensory ®bers in the periphery, possibly in the vagus nerve.
It has previously been shown that some obese subjects have an attenuated release of GLP-1 and enteroglucagon, secreted in parallel with GLP-1 after a meal. 13, 15, 37 Thus, it can be speculated that the lower GLP-1 response in obese subjects after a meal, may result in a shorter period of inter-meal satiety and more frequent food intake to maintain an appropriate individual satiety level. Therefore, GLP-1 administered to obese subjects, may have an anorectic Figure 5 Mean AE s.e.m. plasma peptide YY (PYY) and glucagonlike peptide-1 (C-terminal GLP-1 and N-terminal GLP-1) concentration during glucagon-like peptide-1 (GLP-1, ®lled circles) and saline (®lled squares) infusion in eight obese male subjects. An energy ®xed breakfast (2.4 MJ) was served at 08.00 h and an ad libitum lunch and dinner at 12.00 h and 16.00 h, respectively. By ANOVA with repeated measures, time, treatment and treatment Â time interaction effect: all P`0.001 for PYY, C-and Nterminal GLP-1.
GLP-1, appetite and energy intake E Na Èslund et al and even weight-reducing effect if given over a prolonged period of time. The blood glucose-lowering effect of GLP-1 has not been shown to exhibit tachyphylaxis, when administered intravenously for seven days in man, 38 and so it may be hypothesised that an appetite-reducing effect of GLP-1 should not exhibit tachyphylaxis. However, recent data on longterm ICV administration to rodents is con¯icting. There is evidence of tachyphylaxis, 39 whereas it has been shown that the central pathways involved in the control of food consumption, do not desensitise after chronic exposure to GLP-1. 40 To evaluate the physiological relevance of GLP-1 in weight control, a mouse model with a null mutation of the GLP-1 receptor has been developed. 41 In these knock-out mice, all binding sites and effects of GLP-1 were eliminated. However, no obvious phenotype of these mice was found compared to wild type mice. In control animals, administration of GLP-1 ICV resulted in a similar inhibition of food intake as in rats, 8, 9 whereas no effect was seen in the knock-out mice. 41 Thus, the inhibitory effect of GLP-1 ICV on feeding seems to be mediated via a speci®c receptor interaction in the brain. The lack of expression of the GLP-1 receptor in knock-out mice did not lead to any changes in feeding behaviour, suggesting the presence of redundant signalling systems and potentially adaptive responses in these knock-out mice, which may ®nd an explanation in the postreceptor mechanisms by which exogenous GLP-1 reduces food intake. Thus, it is far too early to speculate if GLP-1 therapy will be effective as a long-term treatment in morbid obesity.
None of the subjects in this study were on any treatment for diabetes, but demonstrated elevated fasting plasma glucose concentrations and hyperinsulinaemia. GLP-1 has previously been shown to reduce plasma glucose concentrations 29 and GLP-1 has been suggested as a treatment for non-insulin dependent diabetes mellitus (NIDDM). 38 Thus, in addition to the reduction in food intake seen by GLP-1, an additional bene®cial effect of GLP-1 is the improvement in glycaemic control seen during GLP-1 infusion in these obese subjects.
Conclusion
In summary, we propose that GLP-1 has a physiological role as a regulator of inter-meal satiety in man, and that GLP-1 administered to obese subjects over eight hours reduces hunger and energy intake. This effect of GLP-1 may be mediated through vagal afferent pathways in concert with a prolonged gastric emptying signalling satiety to the brain.
